Prelude Therapeutics Q2 net loss $31.2M; pauses IV SMARCA2 degrader, focuses on oral PRT7732

Prelude Therapeutics Inc

2025-Q2 EPS reported -$0.83 vs consensus -$0.45 ▼ miss (-85.1%)

Net loss of $31.2M ($0.41 per share) improved from $34.7M ($0.46) in Q2 2024.
Cash, equivalents and marketable securities $77.3M; runway into Q2 2026.
PRT3789 (IV) Phase 1 completed; will only advance with partnership. Oral PRT7732 enrolling 7th cohort (125 mg once daily); initial data by year-end 2025.
KAT6A degrader development candidate selected; IND on track for H1 2026.
R&D expense $25.8M (down from $29.5M); G&A $6.4M (down from $7.7M) YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.